Tempus AI’s (TEM) Buy Rating Reiterated at Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Tempus AI (NASDAQ:TEM) in a research note released on Friday,Benzinga reports. Needham & Company LLC currently has a $75.00 price target on the stock.

TEM has been the subject of several other reports. Freedom Capital raised Tempus AI to a “hold” rating in a research note on Tuesday, June 30th. Piper Sandler raised Tempus AI from a “neutral” rating to an “overweight” rating and upped their target price for the company from $56.00 to $76.00 in a research report on Tuesday, September 1st. The Goldman Sachs Group initiated coverage on Tempus AI in a research report on Monday, September 21st. They issued a “neutral” rating and a $75.00 price target on the stock. Wall Street Zen raised shares of Tempus AI from a “sell” rating to a “hold” rating in a report on Saturday, July 25th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Tempus AI from $45.00 to $70.00 and gave the company a “neutral” rating in a research note on Wednesday, October 14th. Eleven investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Tempus AI currently has a consensus rating of “Hold” and an average target price of $72.37.

Tempus AI Price Performance

Shares of NASDAQ TEM opened at $67.61 on Friday. The company has a debt-to-equity ratio of 3.06, a current ratio of 3.30 and a quick ratio of 3.16. Tempus AI has a 12 month low of $40.77 and a 12 month high of $93.38. The firm’s 50 day simple moving average is $69.24 and its 200-day simple moving average is $57.26. The stock has a market capitalization of $12.20 billion, a price-to-earnings ratio of -46.95 and a beta of 3.54.

Tempus AI (NASDAQ:TEM) last released its quarterly earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.10. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The firm had revenue of $382.49 million for the quarter, compared to analysts’ expectations of $379.69 million. During the same quarter last year, the company earned ($0.22) EPS. The firm’s revenue for the quarter was up 21.6% compared to the same quarter last year. Analysts expect that Tempus AI will post -1.43 EPS for the current year.

Insider Activity

In related news, CEO Eric P. Lefkofsky sold 250,000 shares of the company’s stock in a transaction dated Tuesday, September 22nd. The shares were sold at an average price of $77.47, for a total value of $19,367,500.00. Following the completion of the sale, the chief executive officer owned 100,000 shares of the company’s stock, valued at $7,747,000. This represents a 71.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Ryan M. Bartolucci sold 7,062 shares of the company’s stock in a transaction on Thursday, September 17th. The shares were sold at an average price of $75.00, for a total value of $529,650.00. Following the completion of the sale, the chief accounting officer owned 60,804 shares of the company’s stock, valued at approximately $4,560,300. This trade represents a 10.41% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,280,965 shares of company stock valued at $80,397,564 over the last quarter. 24.26% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. V Square Quantitative Management LLC purchased a new stake in shares of Tempus AI during the 3rd quarter worth about $27,000. EMC Capital Management bought a new stake in shares of Tempus AI in the second quarter valued at approximately $29,000. Ulland Investment Advisors LLC acquired a new stake in Tempus AI in the 3rd quarter worth $41,000. Eastern Bank acquired a new stake in Tempus AI during the third quarter worth about $69,000. Finally, Whittier Trust Co. raised its stake in shares of Tempus AI by 190.0% in the first quarter. Whittier Trust Co. now owns 870 shares of the company’s stock valued at $41,000 after purchasing an additional 570 shares in the last quarter. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Tempus AI News Summary

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Needham reiterates Buy rating: Needham & Company maintained its Buy recommendation and set a $75 price target, implying roughly 11% upside from the cited share price. The call reinforces Wall Street support for Tempus’ growth outlook. Needham analyst recommendations
• Positive Sentiment: Expanded Bristol Myers Squibb relationship: Tempus announced multi-year oncology and AI-data agreements with Bristol Myers Squibb, a major pharmaceutical validation of its clinical-data platform. The collaboration could support recurring data-related revenue and increase Tempus’ role in drug development. Tempus expands Bristol Myers partnership
• Positive Sentiment: New Pathos AI partnership expands neuroscience reach: Tempus is partnering with Pathos AI and Bristol Myers Squibb on medical research, including neurology and neuroscience applications. Pathos’ $237 million financing and approximately $3 billion valuation may increase the visibility and perceived strategic value of Tempus’ data and AI capabilities. Tempus expands neurology data partnership
• Positive Sentiment: Investor commentary remains constructive: Recent analyses describe Tempus as less risky than previously viewed and highlight its proprietary healthcare-data advantage, as well as its involvement with Moderna’s cancer-vaccine efforts. These opinions add momentum, although they are not company financial results. Tempus AI less risky analysis
• Neutral Sentiment: Tempus remains unprofitable and carries elevated volatility, so investors will likely focus on whether these partnerships translate into sustained revenue growth and improved margins. The company’s recent quarterly results showed stronger-than-expected revenue and a narrower-than-expected loss, but execution remains important.

Tempus AI Company Profile

Tempus AI, Inc is a healthcare technology company that uses artificial intelligence and data analytics to support precision medicine. The company combines clinical, molecular and imaging data to help physicians make more informed treatment decisions and to help researchers and biopharmaceutical companies develop therapies.

Its offerings include genomic testing and analysis, such as tissue- and blood-based tests, as well as software tools designed to assist with clinical decision-making, patient matching for clinical trials and the management of healthcare data.